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 Purpose​:​ ​To​ ​compare​ ​the​ ​safety​ ​and​ ​efficacy​ ​of​ ​a​ ​primary​ ​trabeculectomy​ ​with​ ​mitomycin​ ​C​ ​(T)​ ​and​ ​an 
Ahmed​ ​glaucoma​ ​valve​ ​(AGV)​ ​implantation​ ​in​ ​patients​ ​with​ ​Fuchs​ ​heterochromic​ ​iridocyclitis​ ​(FHIC) 
related​ ​glaucoma,​ ​a​ ​rare​ ​complication​ ​of​ ​an​ ​uncommon​ ​form​ ​of​ ​uveitis.  
Design:​ ​​Retrospective​ ​comparative​ ​case​ ​series. 
Method​:​ ​Twenty-six​ ​patients​ ​with​ ​uncontrolled​ ​FHIC-associated​ ​glaucoma​ ​received​ ​T​ ​(n=12)​ ​or​ ​an 
AGV​ ​(n=14).​ ​Primary​ ​outcome​ ​measures​ ​were​ ​the​ ​surgical​ ​success​ ​defined​ ​as​ ​IOP​ ​≤​ ​21​ ​mmHg​ ​and 
decreased​ ​≥​ ​20%​ ​from​ ​the​ ​baseline​ ​and​ ​no​ ​secondary​ ​glaucoma​ ​surgery.​ ​Secondary​ ​outcome 
measures​ ​were​ ​the​ ​number​ ​of​ ​glaucoma​ ​medications,​ ​complications,​ ​best​ ​corrected​ ​visual​ ​acuity 
(BCVA),​ ​and​ ​intraocular​ ​pressure.  
Results:​ ​​The​ ​follow-up​ ​(mean±SD)​ ​was​ ​34.0±17.7​ ​in​ ​T​ ​and​ ​33.4±18.6​ ​months​ ​in​ ​AGV​ ​(p​ ​=​ ​0.837).​ ​The 
cumulative​ ​probability​ ​of​ ​success​ ​rate​ ​at​ ​the​ ​final​ ​follow-up​ ​at​ ​three​ ​years​ ​was​ ​41.7%​ ​for​ ​T​ ​​ ​and​ ​85.7% 
for​ ​AGV.​ ​There​ ​was​ ​no​ ​significant​ ​difference​ ​in​ ​complications​ ​between​ ​the​ ​two​ ​groups​ ​(P>0.05).  
The​ ​mean​ ​preoperative​ ​IOP​ ​in​ ​T​ ​was​ ​23.4±3.3​ ​mmHg​ ​and​ ​21.6±5.2​ ​mmHg​ ​at​ ​the​ ​final​ ​visit​ ​(P=​ ​0.041). 
In​ ​AGV,​ ​the​ ​preoperative​ ​IOP​ ​was​ ​24±7.8​ ​and​ ​17.1±2.6​ ​mmHg​ ​at​ ​the​ ​final​ ​visit​ ​(P=​ ​0.003),​ ​respectively. 
AGV​ ​had​ ​a​ ​significantly​ ​lower​ ​average​ ​IOP​ ​at​ ​the​ ​final​ ​follow-up​ ​visit​ ​compared​ ​to​ ​T​ ​(P=​ ​0.018). 
The​ ​number​ ​of​ ​glaucoma​ ​medications​ ​at​ ​baseline​ ​was​ ​3.3±0.5​ ​in​ ​T​ ​and​ ​3±0.6​ ​in​ ​AGV​ ​(P=​ ​0.233).​ ​This 
decreased​ ​significantly​ ​to​ ​2.4±1.0​ ​and​ ​1.7±0.6​ ​at​ ​the​ ​final​ ​follow-up​ ​(P=​ ​0.008​ ​and​ ​0.002,​ ​respectively). 
Patients​ ​in​ ​AGV​ ​needed​ ​fewer​ ​glaucoma​ ​medications​ ​(P=​ ​0.041).​ ​BCVA​ ​was​ ​equal​ ​in​ ​both​ ​groups​ ​and 
did​ ​not​ ​change​ ​(p>0.05).  
Conclusion​:​ ​Primary​ ​AGV​ ​had​ ​a​ ​higher​ ​success​ ​rate​ ​than​ ​T​ ​in​ ​the​ ​management​ ​of​ ​FHIC-associated 
glaucoma.​ ​The​ ​risk​ ​of​ ​cataract​ ​formation​ ​and​ ​progression​ ​was​ ​significantly​ ​higher​ ​following​ ​T​ ​in​ ​these 
patients. 






Fuchs​ ​heterochromic​ ​iridocyclitis​ ​(FHIC)​ ​is​ ​a​ ​rare​ ​form​ ​of​ ​uveitis.​ ​While​ ​the​ ​incidence​ ​of​ ​all​ ​forms​ ​of 
uveitis​ ​is​ ​approximately​ ​0.035%​ ​of​ ​the​ ​population,​1​​ ​the​ ​incidence​ ​of​ ​FHIC​ ​is​ ​only​ ​about​ ​0.00105%​ ​(3% 
of​ ​all​ ​uveitis​ ​cases)​2,3​​ ​and​ ​occurs​ ​in​ ​both​ ​eyes​ ​in​ ​10%​ ​of​ ​patients.​4​​ ​It​ ​is​ ​characterized​ ​by​ ​a​ ​low-grade 
intraocular​ ​inflammation,​ ​small​ ​stellate​ ​keratic​ ​precipitates,​ ​and​ ​iris​ ​stromal​ ​atrophy.​5​​ ​Recent​ ​evidence 
points​ ​towards​ ​an​ ​association​ ​between​ ​rubella​ ​and​ ​FHIC​6,7​​ ​but​ ​an​ ​association​ ​between​ ​FHIC​ ​and 
toxoplasmosis​ ​and​ ​toxocariasis​ ​has​ ​also​ ​been​ ​reported.​8,9​​ ​Affected​ ​patients​ ​are​ ​often​ ​asymptomatic​ ​for 
years​ ​and​ ​mostly​ ​present​ ​with​ ​symptoms​ ​of​ ​a​ ​cataract​ ​or​ ​floaters​ ​during​ ​the​ ​third​ ​or​ ​fourth​ ​decade​ ​of 
life.​ ​Because​ ​the​ ​presentation​ ​is​ ​often​ ​variable,​ ​FHIC​ ​is​ ​among​ ​the​ ​most​ ​underdiagnosed​ ​conditions​ ​in 
ophthalmology.​10​​ ​Since​ ​there​ ​is​ ​an​ ​average​ ​of​ ​3.7​ ​years​ ​delay​ ​in​ ​diagnosing​ ​FHIC,​ ​it​ ​should​ ​be 
considered​ ​as​ ​a​ ​differential​ ​diagnosis​ ​for​ ​any​ ​young​ ​patient​ ​with​ ​unilateral​ ​low-grade​ ​uveitis​ ​and​ ​good 
visual​ ​acuity.​5​​ ​Although​ ​FHIC​ ​is​ ​frequently​ ​complicated​ ​by​ ​cataract​ ​formation​ ​in​ ​two-thirds​ ​of​ ​patients, 
the​ ​outcome​ ​of​ ​phacoemulsification​ ​and​ ​intraocular​ ​lens​ ​implantation​ ​is​ ​excellent​ ​and​ ​comparable​ ​to 
normal​ ​eyes.​11​​ ​Older​ ​age​ ​and​ ​a​ ​cataract​ ​can​ ​put​ ​patients​ ​with​ ​FHIC​ ​at​ ​risk​ ​for​ ​glaucoma​12​​ ​which​ ​occurs 
in​ ​15​ ​to​ ​59%.​13,14 
Since​ ​anterior​ ​and​ ​posterior​ ​synechiae​ ​are​ ​uncommon​ ​in​ ​this​ ​condition,​ ​angle-closure​ ​mechanisms​ ​do 
not​ ​play​ ​an​ ​important​ ​role​ ​in​ ​the​ ​development​ ​of​ ​glaucoma.​ ​Abnormal​ ​angle​ ​vessels,​ ​physical 
obstruction​ ​of​ ​trabecular​ ​meshwork​ ​by​ ​inflammatory​ ​cells,​ ​disruption​ ​of​ ​uveal​ ​and​ ​juxtacanalicular 
structures,​ ​trabecular​ ​meshwork​ ​fibrosis​ ​and​ ​steroid-induced​ ​ocular​ ​hypertension​ ​are​ ​all​ ​contributing 
causes.​13,15 
FHIC​ ​often​ ​responds​ ​poorly​ ​to​ ​medical​ ​management​ ​requiring​ ​a​ ​surgical​ ​intervention​ ​to​ ​control 
IOP.​11,13,14,16​​ ​There​ ​is​ ​a​ ​paucity​ ​of​ ​literature​ ​regarding​ ​the​ ​best​ ​initial​ ​surgical​ ​approach​ ​in​ ​the 
management​ ​of​ ​FHIC-associated​ ​glaucoma.​ ​The​ ​purpose​ ​of​ ​this​ ​study​ ​was​ ​to​ ​compare​ ​the​ ​outcomes​ ​of 
the​ ​two​ ​most​ ​common​ ​surgical​ ​interventions,​ ​a​ ​glaucoma​ ​drainage​ ​device​ ​implantation​ ​and 
trabeculectomy,​ ​for​ ​glaucoma​ ​caused​ ​by​ ​FHIC.​ ​We​ ​hypothesized​ ​that​ ​Ahmed​ ​glaucoma​ ​drainage 
devices,​ ​a​ ​valved​ ​implant,​ ​would​ ​have​ ​a​ ​lower​ ​failure​ ​rate​ ​but​ ​at​ ​the​ ​expense​ ​of​ ​a​ ​higher​ ​average 
pressure​ ​as​ ​seen​ ​in​ ​other​ ​glaucomas​ ​with​ ​these​ ​modalities.​17  
Methods 
This​ ​study​​ ​was​ ​approved​ ​by​ ​the​ ​ethics​ ​committee​ ​and​ ​the​ ​institutional​ ​review​ ​board​ ​at​ ​the​ ​Ophthalmic 
Research​ ​Center​ ​and​ ​followed​ ​the​ ​tenets​ ​of​ ​the​ ​Declaration​ ​of​ ​Helsinki.​ ​​A​ ​retrospective​ ​chart​ ​review​ ​of 
medical​ ​records​ ​at​ ​the​ ​Labbafinejad​ ​Medical​ ​Center,Tehran,​ ​Iran,​ ​from​ ​2001​ ​through​ ​2017​ ​yielded​ ​26 
patients​ ​with​ ​FHIC-associated​ ​glaucoma​ ​that​ ​either​ ​had​ ​MMC-augmented​ ​trabeculectomy​ ​(T)​ ​or​ ​a 
primary​ ​Ahmed​ ​Glaucoma​ ​Valve​ ​(AGV)​ ​implantation.​ ​FHIC-associated​ ​glaucoma​ ​was​ ​defined​ ​as​ ​cases 
of​ ​previously​ ​known​ ​FHIC​ ​or​ ​diagnosed​ ​as​ ​Fuchs​ ​at​ ​the​ ​time​ ​of​ ​presentation​ ​accompanied​ ​by 
uncontrolled​ ​IOP​ ​and​ ​progressive​ ​glaucomatous​ ​optic​ ​neuropathy.   
Demographic​ ​data​ ​including​ ​age,​ ​gender,​ ​baseline​ ​best​ ​corrected​ ​visual​ ​acuity​ ​(BCVA),​ ​baseline​ ​IOP, 
number​ ​of​ ​medications,​ ​type​ ​of​ ​surgery,​ ​and​ ​surgical​ ​details​ ​were​ ​recorded.​ ​In​ ​all​ ​cases,​ ​surgery​ ​was 
only​ ​performed​ ​when​ ​the​ ​eyes​ ​were​ ​not​ ​inflamed.​18​​ ​Primary​ ​outcome​ ​measures​ ​were​ ​surgical​ ​success 
defined​ ​as​ ​IOP​ ​≤​ ​21​ ​mmHg​ ​and​ ​decreased​ ​≥​ ​20%​ ​from​ ​the​ ​baseline,​ ​no​ ​secondary​ ​glaucoma​ ​surgery, 
and​ ​no​ ​loss​ ​of​ ​light​ ​perception.  
 Secondary​ ​outcome​ ​measures​ ​were​ ​the​ ​rate​ ​of​ ​complications,​ ​cataract​ ​development,​ ​numbers​ ​of 
medications,​ ​and​ ​IOP​ ​reduction.​ ​Hypotony​ ​was​ ​defined​ ​as​ ​IOP​ ​less​ ​than​ ​6​ ​mmHg​ ​at​ ​any​ ​postoperative 
visit,​ ​and​ ​hypertensive​ ​phase​ ​following​ ​AGV​ ​implantation​ ​was​ ​defined​ ​as​ ​an​ ​intraocular​ ​pressure​ ​more 
than​ ​21​ ​mmHg​ ​during​ ​the​ ​first​ ​three​ ​months​ ​after​ ​the​ ​surgery​ ​(with​ ​or​ ​without​ ​medications).​19​​ ​All 
postoperative​ ​data​ ​for​ ​each​ ​surgery​ ​were​ ​documented​ ​until​ ​the​ ​last​ ​follow-up​ ​visit​ ​or​ ​when​ ​a​ ​secondary 
glaucoma​ ​surgery​ ​was​ ​performed. 
Surgical​ ​technique 
Trabeculectomy:​​ ​A​ ​7-0​ ​silk​ ​traction​ ​suture​ ​was​ ​passed​ ​through​ ​the​ ​superior​ ​cornea.​ ​A​ ​conjunctival 
peritomy​ ​was​ ​performed​ ​at​ ​the​ ​supranasal​ ​quadrant​ ​followed​ ​by​ ​Tenon’s​ ​dissection.​ ​Wet​ ​field​ ​cautery 
was​ ​used​ ​to​ ​stop​ ​episcleral​ ​vessels​ ​bleeding.​ ​A​ ​4​ ​by​ ​3​ ​mm​ ​trapezoidal​ ​half​ ​thickness​ ​scleral​ ​flap​ ​was 
created​ ​followed​ ​by​ ​lamellar​ ​dissection​ ​to​ ​peripheral​ ​cornea.​ ​Sponges​ ​soaked​ ​in​ ​0.04%​ ​MMC​ ​were 
applied​ ​for​ ​3​ ​minutes.​ ​After​ ​creating​ ​a​ ​sideport,​ ​a​ ​keratome​ ​was​ ​used​ ​to​ ​enter​ ​the​ ​anterior​ ​chamber 
underneath​ ​the​ ​flap,​ ​and​ ​a​ ​block​ ​of​ ​clear​ ​cornea​ ​was​ ​removed​ ​by​ ​Kelly​ ​punch.​ ​The​ ​scleral​ ​flap​ ​was 
closed​ ​relatively​ ​tightly​ ​with​ ​two​ ​releasable​ ​sutures​ ​so​ ​that​ ​spontaneous​ ​drainage​ ​was​ ​minimal.​ ​The 
conjunctiva​ ​was​ ​closed​ ​with​ ​10-0​ ​nylon​ ​sutures.​ ​At​ ​the​ ​conclusion​ ​of​ ​surgery​ ​betamethasone​ ​and 
cefazolin​ ​were​ ​injected​ ​into​ ​the​ ​subtenon​ ​space​ ​away​ ​from​ ​the​ ​site​ ​of​ ​operation.​ ​The​ ​postoperative 
regimen​ ​consisted​ ​of​ ​chloramphenicol​ ​0.5%​ ​eye​ ​drops​ ​(Sina​ ​Darou​ ​Lab.​ ​Co.,​ ​Tehran,​ ​Iran)​ ​four​ ​times​ ​a 
day​ ​for​ ​one​ ​week​ ​and​ ​betamethasone​ ​0.1%​ ​eye​ ​drops​ ​(Sina​ ​Darou​ ​Lab.​ ​Co.,​ ​Tehran,​ ​Iran)​ ​six​ ​times​ ​a 
day,​ ​which​ ​was​ ​tapered​ ​over​ ​10​ ​weeks. 
Ahmed​ ​glaucoma​ ​valve​ ​implantation​:​ ​A​ ​7-0​ ​silk​ ​traction​ ​suture​ ​was​ ​placed​ ​through​ ​the​ ​superior​ ​clear 
cornea.​ ​The​ ​conjunctiva​ ​was​ ​opened​ ​4​ ​mm​ ​posterior​ ​to​ ​the​ ​limbus​ ​in​ ​the​ ​supratemporal​ ​quadrant,​ ​and 
a​ ​blunt​ ​dissection​ ​of​ ​Tenon​ ​was​ ​performed​ ​using​ ​Westcott​ ​scissors​ ​to​ ​provide​ ​space​ ​for​ ​the​ ​plate 
insertion.​ ​The​ ​device​ ​(Ahmed​ ​glaucoma​ ​drainage​ ​implant,​ ​model​ ​FP7,​ ​New​ ​World​ ​Medical,​ ​Rancho 
Cucamonga,​ ​California)​ ​was​ ​primed​ ​with​ ​2​ ​ml​ ​of​ ​buffered​ ​saline​ ​solution​ ​(BSS)​ ​and​ ​gently​ ​pushed​ ​into 
the​ ​subtenon​ ​space.​ ​The​ ​plate​ ​was​ ​secured​ ​to​ ​the​ ​sclera​ ​10​ ​mm​ ​posterior​ ​to​ ​the​ ​limbus​ ​using​ ​7-0​ ​silk 
sutures.​ ​The​ ​tube​ ​was​ ​trimmed​ ​bevel​ ​up​ ​with​ ​an​ ​estimated​ ​intracameral​ ​length​ ​of​ ​2​ ​mm.​ ​A​ ​23-gauge 
needle​ ​was​ ​inserted​ ​into​ ​the​ ​anterior​ ​chamber​ ​bevel​ ​up,​ ​parallel​ ​to​ ​the​ ​iris​ ​and​ ​1​ ​mm​ ​posterior​ ​to​ ​the 
limbus.​ ​The​ ​tube​ ​was​ ​passed​ ​through​ ​the​ ​tunnel​ ​into​ ​the​ ​anterior​ ​chamber​ ​and​ ​secured​ ​to​ ​the​ ​sclera 
with​ ​a​ ​10-0​ ​nylon​ ​suture.​ ​A​ ​5x8​ ​mm​ ​scleral​ ​patch​ ​graft​ ​was​ ​placed​ ​over​ ​the​ ​tube.​ ​Tenon’s​ ​capsule​ ​and 
the​ ​conjunctiva​ ​were​ ​closed​ ​using​ ​a​ ​running​ ​10-0​ ​nylon​ ​mattress​ ​suture.​ ​At​ ​the​ ​end​ ​of​ ​the​ ​surgery,​ ​0.5 
mL​ ​of​ ​subtenon​ ​triamcinolone​ ​(40​ ​mg/mL)​ ​was​ ​injected​ ​next​ ​to​ ​the​ ​plate​ ​in​ ​four​ ​patients. 
Betamethasone​ ​(4​ ​mg)​ ​and​ ​cefazolin​ ​(50​ ​mg)​ ​were​ ​injected​ ​into​ ​inferior​ ​subconjunctival​ ​space​ ​upon 
conclusion​ ​of​ ​the​ ​surgery.​ ​The​ ​postoperative​ ​regimen​ ​comprised​ ​chloramphenicol​ ​0.5%​ ​eye​ ​drops​ ​four 
times​ ​daily​ ​for​ ​one​ ​week​ ​and​ ​betamethasone​ ​0.1%​ ​drops​ ​six​ ​times​ ​daily​ ​to​ ​be​ ​tapered​ ​gradually​ ​over 
six​ ​weeks. 
Statistics 
To​ ​test​ ​for​ ​a​ ​difference​ ​between​ ​the​ ​two​ ​groups​ ​at​ ​baseline,​ ​we​ ​used​ ​the​ ​t-test,​ ​Mann-Whitney, 
Chi-Square​ ​and​ ​Fisher​ ​exact​ ​test.​ ​We​ ​used​ ​a​ ​General​ ​linear​ ​model​ ​and​ ​Ordinal​ ​logistic​ ​regression​ ​to 
compare​ ​the​ ​groups​ ​adjusted​ ​for​ ​the​ ​baseline.​ ​Changes​ ​within​ ​groups​ ​were​ ​evaluated​ ​using​ ​paired 
t-test​ ​and​ ​Wilcoxon​ ​signed​ ​rank​ ​test.​ ​A​ ​P​ ​-​ ​value​ ​less​ ​than​ ​0.05​ ​was​ ​considered​ ​statistically​ ​significant. 
All​ ​statistical​ ​analyses​ ​were​ ​performed​ ​with​ ​SPSS​ ​software​ ​(IBM​ ​Corp.​ ​Released​ ​2016.​ ​IBM​ ​SPSS 
 Statistics​ ​for​ ​Windows,​ ​Version​ ​24.0.​ ​Armonk,​ ​NY:​ ​IBM​ ​Corp.)​ ​Data​ ​was​ ​described​ ​as​ ​frequency 
(percent),​ ​mean±standard​ ​deviation,​ ​median​ ​and​ ​range.  
Results 
Twenty-six​ ​patients​ ​were​ ​included​ ​for​ ​the​ ​final​ ​analysis.​ ​Fourteen​ ​patients​ ​were​ ​male​ ​(53.8%).​ ​There 
were​ ​12​ ​trabeculectomies​ ​and​ ​14​ ​AGV​ ​surgeries.​ ​All​ ​cases​ ​were​ ​primary​ ​surgeries​ ​with​ ​no​ ​history​ ​of 
glaucoma​ ​surgery.​ ​There​ ​was​ ​no​ ​significant​ ​difference​ ​regarding​ ​sex,​ ​age,​ ​IOP,​ ​BCVA,​ ​and​ ​numbers​ ​of 
glaucoma​ ​medications​ ​at​ ​baseline​ ​(Table​ ​1).​ ​The​ ​mean​ ​age​ ​at​ ​the​ ​time​ ​of​ ​surgery​ ​for​ ​T​ ​was​ ​47.5±6.1 
years​ ​and​ ​for​ ​AGV​ ​was​ ​45.9±9.3​ ​years​ ​(P=​ ​0.608).​ ​Ten​ ​patients​ ​(83.3%)​ ​in​ ​T​ ​were​ ​phakic​ ​and​ ​14 
patients​ ​(100%)​ ​in​ ​AGV​ ​were​ ​phakic​ ​(P=0.203).​ ​Preoperatively,​ ​the​ ​angle​ ​was​ ​open​ ​in​ ​all​ ​patients​ ​upon 
gonioscopy.​ ​Two​ ​patients​ ​in​ ​T​ ​had​ ​a​ ​phacoemulsification​ ​and​ ​lens​ ​implantation​ ​in​ ​the​ ​same​ ​session. 
The​ ​mean​ ​follow-up​ ​was​ ​34±17.7​ ​months​ ​in​ ​T​ ​and​ ​33.4±18.6​ ​months​ ​in​ ​AGV​ ​(P=​ ​0.837). 
Surgical​ ​success​ ​at​ ​the​ ​final​ ​follow-up​ ​was​ ​41.7%​ ​for​ ​T​ ​surgery​ ​and​ ​85.7%​ ​in​ ​AGV​ ​(P=​ ​0.025).​ ​IOP 
decreased​ ​significantly​ ​from​ ​24±7.8​ ​mmHg​ ​at​ ​baseline​ ​to​ ​17.14±2.6​ ​mmHg​ ​at​ ​the​ ​final​ ​follow-up​ ​in​ ​AGV 
(P=​ ​0.003).​ ​The​ ​corresponding​ ​numbers​ ​for​ ​T​ ​were​ ​23.4±3.3​ ​and​ ​21.58±5.2​ ​mmHg,​ ​respectively​ ​(P= 
0.041,​ ​Table​ ​2).​ ​AGV​ ​had​ ​a​ ​significantly​ ​lower​ ​average​ ​IOP​ ​at​ ​the​ ​final​ ​follow-up​ ​visit​ ​compared​ ​to​ ​T 
(P=​ ​0.018).​ ​Three​ ​patients​ ​in​ ​T​ ​and​ ​one​ ​in​ ​AGV​ ​needed​ ​a​ ​surgical​ ​revision​ ​specifically​ ​to​ ​control​ ​high 
intraocular​ ​pressure.​ ​AGV​ ​was​ ​used​ ​as​ ​a​ ​secondary​ ​glaucoma​ ​surgery​ ​in​ ​all​ ​these​ ​cases.​ ​The​ ​number 
of​ ​glaucoma​ ​medications​ ​decreased​ ​significantly​ ​from​ ​3±0.6​ ​at​ ​baseline​ ​to​ ​1.71±0.6​ ​at​ ​the​ ​final 
follow-up​ ​visit​ ​in​ ​AGV​ ​(P=​ ​0.002).​ ​The​ ​medications​ ​in​ ​T​ ​were​ ​3.3±0.5​ ​at​ ​baseline​ ​and​ ​2.41±1.01​ ​at​ ​the 
conclusion​ ​of​ ​the​ ​study,​ ​respectively​ ​(P=​ ​0.008). 
Patients​ ​in​ ​AGV​ ​needed​ ​fewer​ ​glaucoma​ ​medications​ ​at​ ​the​ ​final​ ​follow-up​ ​(P=​ ​0.041).​ ​Kaplan–Meier 
survival​ ​curves​ ​for​ ​the​ ​two​ ​groups​ ​are​ ​shown​ ​in​ ​Figure​ ​1.​ ​The​ ​estimated​ ​mean​ ​survival​ ​time​ ​was​ ​20.8 
months​ ​for​ ​AGV​ ​and​ ​only​ ​12.7​ ​months​ ​for​ ​T​ ​(P=​ ​0.002).​ ​The​ ​reason​ ​for​ ​failure​ ​in​ ​T​ ​was​ ​bleb​ ​fibrosis. 
Five​ ​patients​ ​(37.5%)​ ​in​ ​AGV​ ​experienced​ ​an​ ​early​ ​hypertensive​ ​phase. 
Triamcinolone​ ​had​ ​no​ ​impact​ ​on​ ​IOP​ ​(P=​ ​0.320).​ ​The​ ​most​ ​frequent​ ​complication​ ​in​ ​both​ ​groups​ ​was 
hyphema​ ​(Table​ ​3).​ ​Five​ ​patients​ ​(41.6%)​ ​in​ ​T​ ​and​ ​three​ ​patients​ ​in​ ​AGV​ ​(21.4%)​ ​developed​ ​hyphema 
(P=​ ​0.292)​ ​which​ ​could​ ​be​ ​managed​ ​conservatively.​ ​One​ ​patient​ ​in​ ​AGV​ ​and​ ​three​ ​in​ ​T​ ​established 
choroidal​ ​effusions​ ​and​ ​had​ ​to​ ​be​ ​drained​ ​in​ ​one​ ​AGV​ ​patient.​ ​One​ ​patient​ ​in​ ​each​ ​group​ ​developed 
endophthalmitis.​ ​The​ ​endophthalmitis​ ​in​ ​AGV​ ​was​ ​preceded​ ​by​ ​tube​ ​exposure.​ ​The​ ​patient​ ​underwent 
vitrectomy,​ ​and​ ​the​ ​device​ ​was​ ​removed.​ ​A​ ​new​ ​AGV​ ​was​ ​implanted​ ​in​ ​the​ ​infranasal​ ​location​ ​in​ ​the 
same​ ​session.​ ​Although​ ​the​ ​endophthalmitis​ ​in​ ​T​ ​could​ ​be​ ​controlled​ ​by​ ​an​ ​injection​ ​of​ ​intravitreal 
antibiotics​ ​and​ ​a​ ​corticosteroid​ ​(vancomycin​ ​(25​ ​mg​ ​in​ ​0.5​ ​ml),​ ​ceftazidime​ ​(100​ ​mg​ ​in​ ​0.5​ ​ml)​ ​and 
dexamethasone​ ​(6​ ​mg​ ​in​ ​0.25​ ​ml)​ ​injected​ ​as​ ​a​ ​bolus),​ ​a​ ​glaucoma​ ​drainage​ ​device​ ​was​ ​needed.​ ​Two 
AGV​ ​patients​ ​experienced​ ​endothelial​ ​touch,​ ​and​ ​one​ ​of​ ​them​ ​underwent​ ​tube​ ​shortening​ ​due​ ​to​ ​early 
corneal​ ​decompensation.​ ​Hypotony​ ​was​ ​observed​ ​in​ ​2​ ​cases​ ​in​ ​T​ ​in​ ​the​ ​early​ ​postoperative​ ​period, 
which​ ​resolved​ ​without​ ​a​ ​surgical​ ​intervention​ ​within​ ​one​ ​month.​ ​There​ ​was​ ​no​ ​significant​ ​difference 
between​ ​the​ ​rate​ ​of​ ​complications​ ​between​ ​the​ ​two​ ​groups​ ​(Table​ ​3).​ ​None​ ​of​ ​the​ ​listed​ ​complications 
were​ ​significant​ ​factors​ ​for​ ​surgical​ ​failure​ ​in​ ​AGV​ ​or​ ​T.​ ​A​ ​cataract​ ​extraction​ ​was​ ​indicated​ ​in​ ​five 
patients​ ​in​ ​T​ ​and​ ​in​ ​only​ ​one​ ​patient​ ​in​ ​AGV.​ ​The​ ​mean​ ​time​ ​between​ ​trabeculectomy​ ​and​ ​cataract 
surgery​ ​was​ ​9.1±4.3​ ​months. 
 Discussion 
In​ ​this​ ​retrospective​ ​study,​ ​we​ ​evaluated​ ​the​ ​outcome​ ​of​ ​two​ ​common​ ​surgeries​ ​for​ ​FHIC-associated 
glaucoma,​ ​a​ ​valved​ ​tube​ ​shunt​ ​(AGV)​ ​and​ ​trabeculectomy​ ​with​ ​mitomycin​ ​C​ ​(T).​ ​Although​ ​FHIC​ ​is​ ​rare, 
occurring​ ​only​ ​in​ ​about​ ​0.00105%​ ​of​ ​the​ ​population,​2,3​​ ​and​ ​the​ ​course​ ​typically​ ​mild,​ ​almost​ ​50%​ ​of 
patients​ ​with​ ​FHIC​ ​develop​ ​glaucoma​12–14,20​​ ​and​ ​require​ ​aggressive​ ​management.​ ​We​ ​found​ ​that​ ​AGV 
had​ ​a​ ​significantly​ ​higher​ ​success​ ​rate​ ​compared​ ​to​ ​trabeculectomy,​ ​confirming​ ​our​ ​hypothesis. 
Patients​ ​also​ ​needed​ ​fewer​ ​glaucoma​ ​medications​ ​in​ ​AGV​ ​while​ ​the​ ​complication​ ​rate​ ​was​ ​similar.  
Most​ ​glaucoma​ ​patients​ ​have​ ​an​ ​open​ ​angle​ ​on​ ​gonioscopy.​ ​Decreased​ ​outflow​ ​is​ ​instead​ ​caused​ ​by 
inflammatory​ ​cells,​ ​fibrotic​ ​changes​ ​of​ ​the​ ​trabecular​ ​meshwork,​ ​and​ ​long-term​ ​steroid​ ​use​ ​​13–15​.​ ​The 
management​ ​of​ ​FHIC-associated​ ​glaucoma​ ​is​ ​challenging.​21​​ ​In​ ​a​ ​study​ ​by​ ​Liesegang​ ​et​ ​al.​ ​66%​ ​of 
patients​ ​with​ ​FHIC-associated​ ​glaucoma​ ​needed​ ​a​ ​surgical​ ​intervention​ ​and​ ​did​ ​so​ ​earlier​ ​in​ ​life​ ​than 
individuals​ ​with​ ​primary​ ​open​ ​angle​ ​glaucoma.​16​​ ​Laser​ ​trabeculoplasty​ ​is​ ​relatively​ ​contraindicated 
because​ ​it​ ​can​ ​exacerbate​ ​the​ ​inflammation,​ ​cause​ ​bleeding​ ​from​ ​neovascularization​ ​of​ ​the​ ​angle​ ​and 
induce​ ​peripheral​ ​anterior​ ​synechiae.​22  
When​ ​the​ ​uveitis​ ​is​ ​only​ ​mildly​ ​active,​ ​trabeculectomy​ ​can​ ​be​ ​performed​ ​to​ ​quickly​ ​lower​ ​IOP,​ ​including 
in​ ​FHIC,​23​​ ​despite​ ​the​ ​risk​ ​of​ ​bleb​ ​failure​24​​ ​but​ ​the​ ​success​ ​rate​ ​is​ ​less​ ​than​ ​30%​ ​at​ ​five​ ​years,​25,26​​ ​far 
worse​ ​than​ ​in​ ​primary​ ​open​ ​angle​ ​glaucoma.​27​​ ​Although​ ​FHIC​ ​is​ ​not​ ​typically​ ​characterized​ ​by​ ​severe 
inflammation,​ ​trabeculectomy​ ​outcomes​ ​have​ ​been​ ​reported​ ​to​ ​be​ ​worse.​13,14​​ ​The​ ​high​ ​rate​ ​of​ ​hyphema 
in​ ​our​ ​series​ ​likely​ ​contributed​ ​to​ ​this​ ​because​ ​blood​ ​can​ ​reduce​ ​the​ ​bleb​ ​size​ ​in​ ​trabeculectomy​28,29​​ ​but 
not​ ​in​ ​tube​ ​shunts.​ ​Hyphema​ ​commonly​ ​occurs​ ​in​ ​FHIC​ ​because​ ​of​ ​the​ ​angle​ ​neovascularization​ ​in 
FHIC​30​​ ​and​ ​rupture​ ​of​ ​these​ ​fragile​ ​vessels​ ​following​ ​IOP​ ​reduction.​5​​ ​Cataract​ ​is​ ​another​ ​common 
occurrence​ ​in​ ​FHIC​ ​and​ ​has​ ​an​ ​increased​ ​incidence​ ​after​ ​trabeculectomy.​ ​In​ ​our​ ​study,​ ​five​ ​out​ ​of​ ​ten 
patients​ ​required​ ​cataract​ ​surgery.​ ​The​ ​high​ ​rate​ ​of​ ​cataract​ ​formation​ ​after​ ​trabeculectomy​ ​appears​ ​to 
be​ ​an​ ​under-reported​ ​risk​ ​of​ ​failure​ ​of​ ​trabeculectomy​ ​in​ ​FHIC-associated​ ​glaucoma.​ ​For​ ​this​ ​reason, 
same​ ​session​ ​cataract​ ​removal​ ​should​ ​be​ ​considered​ ​because​ ​modern​ ​phacoemulsification​ ​at​ ​the​ ​time 
of​ ​glaucoma​ ​surgery​ ​may​ ​have​ ​only​ ​a​ ​negligible​ ​impact​ ​on​ ​IOP​ ​outcomes.​31 
The​ ​reported​ ​intermediate​ ​success​ ​rate​ ​for​ ​glaucoma​ ​drainage​ ​devices​ ​in​ ​uveitic​ ​glaucoma​ ​is​ ​between 
66%​ ​to​ ​85%.​32–34​​ ​In​ ​a​ ​study​ ​by​ ​Tan​ ​et​ ​al.,​ ​the​ ​short​ ​and​ ​long-term​ ​success​ ​rate​ ​of​ ​non-valved​ ​Baerveldt 
implants​ ​in​ ​uveitic​ ​glaucoma​ ​was​ ​89%​ ​and​ ​75%,​ ​respectively.​35​​ ​In​ ​another​ ​study,​ ​Satana​ ​et​ ​al.​ ​used 
valved​ ​Ahmed​ ​implants​ ​in​ ​14​ ​patients​ ​with​ ​uveitic​ ​glaucoma​ ​secondary​ ​to​ ​Behcet​ ​disease​ ​and​ ​reported 
the​ ​cumulative​ ​probability​ ​of​ ​surgical​ ​success​ ​rate​ ​of​ ​90.9%​ ​at​ ​18​ ​months​ ​follow-up.​33​​ ​Kwon​ ​et​ ​al. 
examined​ ​the​ ​outcome​ ​of​ ​AGV​ ​implantation​ ​in​ ​28​ ​patients​ ​with​ ​uveitic​ ​glaucoma​ ​including​ ​FHIC​ ​and 
reported​ ​a​ ​success​ ​rate​ ​of​ ​75%​ ​during​ ​two​ ​years​ ​follow-up.​36​​ ​​Voykov​ ​and​ ​colleagues​ ​assessed​ ​the​ ​short 
and​ ​intermediate-term​ ​success​ ​rate​ ​of​ ​AGV​ ​implantation​ ​in​ ​17​ ​patients​ ​with​ ​FHIC-​ ​associated 
glaucoma.​37​​ ​Qualified​ ​success​ ​defined​ ​as​ ​6​ ​mmHg​ ​≤​ ​IOP​ ​≤21​ ​mmHg​ ​was​ ​achieved​ ​in​ ​58.3%​ ​of​ ​patients 
after​ ​one​ ​year​ ​and​ ​only​ ​38.4%​ ​after​ ​three​ ​years​ ​but​ ​88%​ ​of​ ​patients​ ​had​ ​conjunctival​ ​scarring​ ​from​ ​prior 
procedures,​ ​a​ ​known​ ​risk​ ​factor.​38​​ ​This​ ​may​ ​also​ ​explain​ ​the​ ​rate​ ​of​ ​complications​ ​(23%​ ​tube​ ​exposure, 
23%​ ​device​ ​exposure,​ ​6%​ ​endophthalmitis,​ ​6%​ ​diplopia,​ ​11.7%​ ​hypotony)​ ​in​ ​the​ ​mentioned​ ​study.  
Our​ ​results​ ​indicate​ ​that​ ​primary​ ​AGV​ ​has​ ​a​ ​higher​ ​cumulative​ ​probability​ ​of​ ​success​ ​in​ ​FHIC. 
Regardless,​ ​consistent​ ​with​ ​prior​ ​studies​ ​​34,39​​ ​our​ ​complication​ ​rate​ ​was​ ​high.​ ​This​ ​highlights​ ​how 
challenging​ ​and​ ​unpredictable​ ​uveitis​ ​is​ ​even​ ​though​ ​FHIC​ ​is​ ​a​ ​relatively​ ​mild​ ​form​ ​of​ ​uveitis.​ ​Given​ ​the 
high​ ​rate​ ​of​ ​complications​ ​and​ ​the​ ​patients’​ ​middle​ ​age,​ ​microincisional​ ​procedures​ ​should​ ​be 
 considered​ ​for​ ​FHIC​ ​that​ ​have​ ​been​ ​proven​ ​to​ ​be​ ​safe​ ​and​ ​effective​ ​in​ ​other​ ​mild-to-moderate​ ​forms​ ​of 
uveitic​ ​glaucoma,​40,41​​ ​and​ ​appropriate​ ​for​ ​a​ ​range​ ​of​ ​glaucoma​ ​severity.​42​​ ​The​ ​occurrence​ ​of​ ​a 
hypertensive​ ​phase​ ​in​ ​the​ ​current​ ​study​ ​is​ ​lower​ ​than​ ​the​ ​47%​ ​incidence​ ​rate​ ​reported​ ​by​ ​Voykov​ ​et​ ​al.​37 
The​ ​lower​ ​rate​ ​could​ ​partially​ ​be​ ​explained​ ​by​ ​modulating​ ​of​ ​encapsidation​ ​and​ ​inflammation​ ​by 
triamcinolone​ ​used​ ​in​ ​several​ ​patients​ ​here​ ​although​ ​contradictory​ ​results​ ​have​ ​been​ ​reported.​43,44​​ ​Bleb 
vascularity​ ​is​ ​a​ ​recently​ ​identified​ ​risk​ ​factor​ ​for​ ​bleb​ ​failure​27​​ ​that​ ​we​ ​did​ ​not​ ​examine​ ​here.​ ​An 
intensified​ ​treatment​ ​for​ ​this​ ​problem​ ​can​ ​include​ ​bevacizumab​ ​that​ ​can​ ​be​ ​used​ ​subconjunctivally​45 
instead​ ​of​ ​intravitreally.​46​​ ​Another​ ​explanation​ ​for​ ​the​ ​lower​ ​incidence​ ​of​ ​early​ ​hypertension​ ​may​ ​be​ ​the 
start​ ​of​ ​aqueous​ ​suppressant​ ​to​ ​reduce​ ​fibroblast​ ​stimulation​ ​from​ ​stretch​ ​and​ ​cytokines.​47  
Limitations​ ​of​ ​this​ ​study​ ​are​ ​the​ ​relatively​ ​small​ ​patient​ ​number​ ​dictated​ ​by​ ​the​ ​overall​ ​rareness​ ​of​ ​FHIC, 
a​ ​retrospective​ ​design​ ​and​ ​use​ ​of​ ​triamcinolone​ ​in​ ​some​ ​patients.​ ​Although​ ​the​ ​anterior​ ​chamber​ ​cell 
reaction​ ​in​ ​FHIC​ ​is​ ​not​ ​as​ ​prominent​ ​as​ ​in​ ​other​ ​uveitic​ ​glaucomas,​ ​we​ ​could​ ​have​ ​systematically 
measured​ ​the​ ​anterior​ ​chamber​ ​cell​ ​reaction​ ​to​ ​see​ ​whether​ ​it​ ​correlated​ ​with​ ​survival.  
In​ ​conclusion,​ ​this​ ​study​ ​shows​ ​that​ ​Ahmed​ ​glaucoma​ ​drainage​ ​devices​ ​are​ ​superior​ ​to​ ​trabeculectomy 
in​ ​FHIC-associated​ ​glaucoma.​ ​The​ ​relatively​ ​high​ ​complication​ ​rate​ ​is​ ​consistent​ ​with​ ​prior​ ​reports​ ​and 
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 Tables​ ​and​ ​Figures 
Table​ ​1:​ ​Baseline​ ​clinical​ ​characteristics​ ​of​ ​patients​ ​in​ ​T​ ​and​ ​AGV.  
 
  All T AGV p 
Age Mean​ ​±​ ​SD 46.6​ ​±​ ​7.9 47.5​ ​±​ ​6.1 45.9​ ​±​ ​9.3 0.608† 
 Median​ ​(range) 48​ ​(32​ ​to​ ​60) 48.5​ ​(36​ ​to​ ​56) 47​ ​(32​ ​to​ ​60)  
Gender Male 14​ ​(53.8%) 8​ ​(66.7%) 6​ ​(42.9%) 0.267* 
 Female 12​ ​(46.2%) 4​ ​(33.3%) 8​ ​(57.1%)  
Lens​ ​status Phakic 24​ ​(92.3%) 10​ ​(83.3%) 14​ ​(100.0%) 0.203** 
 Pseudophakic 2​ ​(7.7%) 2​ ​(16.7%) 0​ ​(0.0%)  
BCVA Mean​ ​±​ ​SD 0.29​ ​±​ ​0.3 0.3​ ​±​ ​0.34 0.27​ ​±​ ​0.27 0.835‡ 
 Median​ ​(range) 0.15​ ​(0.05​ ​to​ ​1.1) 0.15​ ​(0.05​ ​to​ ​1) 0.19​ ​(0.05​ ​to​ ​1.1)  
IOP Mean​ ​±​ ​SD 23.7​ ​±​ ​6 23.4​ ​±​ ​3.3 24​ ​±​ ​7.8 0.801† 
 Median​ ​(range) 22​ ​(14​ ​to​ ​42) 23​ ​(18​ ​to​ ​28) 21​ ​(14​ ​to​ ​42)  
Medications Mean​ ​±​ ​SD 3.1​ ​±​ ​0.5 3.3​ ​±​ ​0.5 3​ ​±​ ​0.6 0.233‡ 
 Median​ ​(range) 3​ ​(2​ ​to​ ​4) 3​ ​(3​ ​to​ ​4) 3​ ​(2​ ​to​ ​4)  
Follow-up Mean​ ​±​ ​SD 33.7​ ​±​ ​17.8 34​ ​±​ ​17.7 33.4​ ​±​ ​18.6 0.837‡ 
 Median​ ​(range) 29.5​ ​(11​ ​to​ ​89) 30​ ​(11​ ​to​ ​80) 29.5​ ​(13​ ​to​ ​89)  
 
BCVA:​ ​best​ ​corrected​ ​visual​ ​acuity.​ ​IOP:​ ​intraocular​ ​pressure.​ ​†​ ​Based​ ​on​ ​t-test.​ ​‡​ ​Based​ ​on 
Mann-Whitney​ ​test.​ ​*​ ​Based​ ​on​ ​Chi-Square​ ​test. 
**​ ​Based​ ​on​ ​Fisher​ ​exact​ ​test. 
  






P  T AGV Lower Upper 
BCVA Baseline 0.3​ ​±​ ​0.34 0.27​ ​±​ ​0.27 0.03 -0.21 0.28 0.835‡ 
 Final​ ​visit 0.34​ ​±​ ​0.35 0.44​ ​±​ ​0.67 -0.1 -0.55 0.34 0.417§ 
 Change -0.03​ ​±​ ​0.08 -0.17​ ​±​ ​0.57 0.14 -0.21 0.48  
 Within​ ​P  0.006 0.004     
        
IOP Baseline 23.4​ ​±​ ​3.3 24​ ​±​ ​7.8 -0.6 -5.6 4.4 0.801† 
 Final​ ​visit 21.58​ ​±​ ​5.2 17.14​ ​±​ ​2.6 0.6 -2.4 3.6 0.018§ 
 Within​ ​P$ 0.041 0.003     
        
Medication Baseline 3.3​ ​±​ ​0.5 3​ ​±​ ​0.6 0.3 -0.2 0.7 0.233‡ 
 Final​ ​visit 2.41​ ​±​ ​1.01 1.71​ ​±​ ​0.6 0.2 -0.5 1 0.041¥ 
 Within​ ​P  0.008 0.002     
        
Baseline​ ​lens 
status Phakic 10​ ​(83.3%) 14​ ​(100.0%) 16.70% 10.4% -4.7% 0.203** 
 Pseudophakic 2​ ​(16.7%) 0​ ​(0.0%)     
Final​ ​visit​ ​lens 
status Phakic 3​ ​(25.0%) 13​ ​(92.9%) 67.90% 14.3% 38.3% 0.001** 
 Pseudophakic 9​ ​(75.0%) 1​ ​(7.1%)     
        
Success​ ​rate​ ​at 
final​ ​visit  5​ ​(41.7%) 12​ ​(85.7%) -22.60% 19.9% -63.7% 0.025** 
 
†​ ​Based​ ​on​ ​t-test.​ ​‡​ ​Based​ ​on​ ​Mann-Whitney​ ​test.​ ​*​ ​Based​ ​on​ ​Chi-Square​ ​test.​ ​**​ ​Based​ ​on​ ​Fisher​ ​exact 
test.​ ​§​ ​Adjusted​ ​for​ ​the​ ​baseline,​ ​based​ ​on​ ​General​ ​linear​ ​model.​ ​​ ​¥​ ​Adjusted​ ​for​ ​the​ ​baseline,​ ​based​ ​on 







 Table​ ​3:​ ​Postoperative​ ​complications​ ​in​ ​T​ ​and​ ​AGV. 
 
 T AGV P​ ​value 
Early​ ​hypotony​ ​(within​ ​3​ ​months 
postoperatively) 2 none 0.31 
Late​ ​hypotony​ ​(after​ ​3​ ​months​ ​postoperatively) none none  
Hyphema 5 3 0.292 
Choroidal​ ​effusion 3 1 0.246 
Corneal​ ​decompensation 0 1 0.213 
Endophthalmitis 1 1  
Tube​ ​exposure​ ​(AGV​ ​only) N/A 2 N/A 
Tube-cornea​ ​touch​ ​(AGV​ ​only) N/A 2 N/A 
Bleb​ ​leakage​ ​(T​ ​only) 3 N/A N/A 





Figure 1: ​Kaplan–Meier survival curve for trabeculectomy (Trab) (solid line) and Ahmed Glaucoma             
Valve (AGV) (dotted line) surgeries for FHIC-associated glaucoma in this study. Log-rank ​P = 0.002.               
Estimated mean survival time for Trab is 12.7 months ​with 95% confidence interval (8.5 to 16.9).                
Estimated mean survival ​time for GDI surgery is 20.8 months with 95% confidence interval ​(17.2 to                
24.4). 
 
 
 
  
 
 
 
